从“巨创”到“微创”——微创瓣膜疾病治疗进展

From"Mega-invasive"to"Minimally invasive"-Progress in the treatment of minimally invasive valve disease

瓣膜性心脏病(valvular heart disease,VHD)的人群患病率在逐年增加,迄今为止手术治疗是其最为有效的治疗手段。随着对疾病发病机制认识的不断深入,以及材料和技术的不断进步,外科手术和介入治疗方式也在不断优化,不同的手术方式使VHD患者有着更加多元化的治疗选择,这就要求心脏外科医生应当根据患者情况结合现有最新的研究证据制定个体化最佳治疗方案,包括瓣膜疾病终身管理策略。

The prevalence of valvular heart disease(VHD)is increasing year by year,and surgery is by far the most effective treatment.With deeper cognition about mechanisms of valve disease and the continuous progress of materials and technology,surgical procedures and interventional procedures are also being optimized.Different minimally invasive surgical methods and transcatheter theraputic strategy make the treatment of patients with VHD more diversified options,which requires cardiac surgeons to develop a personalized treatment schemes or even life-long management strategies for valvular disease according to individual patient's special condition combined with the latest theraputic evidence.